COVID-19 NanoAb

N/A

Report date: 2023/09/22 10:49:08

Base Information

Drug NameCOVID-19 NanoAb
Drug Alias NameCOVID-19 nanobodiesCOVID-19 nanosized antibodiesCOVID-19 VHH antibodiesAnti-SARS-CoV-2 NanoAb
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)
Mechanisms of ActionVirus internalization inhibitorsSARS-CoV-2 Spike glycoprotein receptor binding domain modulators
TargetsSARS-CoV-2 Spike glycoprotein receptor binding domain
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIsrael
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesScinai Immunotherapeutics LtdUniversity Medical Center GottingenThe Max Planck Society
China Registration ClassN/A

Develop Information

Active CompaniesScinai Immunotherapeutics Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A